Table 2 Patient characteristics at diagnosis and at euthyroidism for group A (decrease in plasma FT3I after initiation of levothyroxine) and group B (increase or no change in plasma FT3I after initiation of levothyroxine)

Age at diagnosis (years)

44.6 ± 15.1

52.2 ± 13.8

0.047*

Weight at HQRL assessment (kg)

78.9 ± 13.7

76.8 ± 14.3

0.570

Gender (n)

 Male

7

6

 Female

17

37

0.131

Intake of LT4 (n)

 Morning

3

8

 Bedtime

21

35

0.734

Brand of LT4 (n)

 Eltroxin®

23

32

 Euthyrox®

2

10

0.186

Dose of LT4 at euthyroidism

96.5 ± 30.7

103.4 ± 30.1

0.44

Smoker at diagnosis (n)

 Never

9

13

 Smoker

4

5

 Ex-smoker

11

25

0.753

Severity of hypothyroidism at diagnosis (n)

 Subclinical

18

18

 Overt

6

25

0.011*

Time to euthyroidism (days)

125 ± 102

110 ± 58

0.492

LogTSH at diagnosis

0.94 ± 0.26

1.09 ± 0.39

0.071

 Anti-log TSH, mU/L

8.7

12.3

Total T3 at diagnosis, nmol/L

1.69 ± 0.33

1.55 ± 0.31

0.091

Total T4 at diagnosis, nmol/L

70.25 ± 18.1

66.22 ± 19.3

0.38

T4 uptake at diagnosis

1.03 ± 0.15

1.12 ± 0.13

0.017*

FT4I at diagnosis, nmol/L

68.2 ± 12.2

59.5 ± 14.4

0.011*

FT3I at diagnosis nmol/L

1.66 ± 0.22

1.40 ± 0.25

< 0.001*

FT4I/ logTSH at diagnosis

78.7 ± 27.7

63.01 ± 27.7

0.031*

FT4I/FT3i ratio at diagnosis

41.8 ± 8.6

42.7 ± 8.6

0.693

LogTSH at euthyroidism

0.27 ± 0.30

0.33 ± 0.23

0.47

 Anti-log TSH, mU/L

1.9

2.1

Total T3 at euthyroidism, nmol/L

1.51 ± 0.29

1.58 ± 0.23

0.323

Total T4 at euthyroidism, nmol/L

98.9 ± 19.0

94.72 ± 17.2

0.371

T4 uptake at euthyroidism

1.05 ± 0.16

1.02 ± 0.09

0.496

FT4I at euthyroidism, nmol/L

95.2 ± 16.9

92.4 ± 14.0

0.51

FT3I at euthyroidism nmol/L

1.55 ± 0.21

1.45 ± 0.24

0.098

FT4I/FT3i ratio at euthyroidism

66.5 ± 11.9

60.4 ± 10.3

0.043*

LogAnti-TPO at diagnosis

2.79 ± 0.57

2.84 ± 0.51

0.927

 Anti-log anti-TPO at diagnosis, kIU/L

616

692

Time from diagnosis to HRQL assessment (days)

66 ± 48

74 ± 52

0.499